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Genomic landscape of high-grade meningiomas
Wenya Linda Bi1,2,3, Noah F. Greenwald 1,2,3, Malak Abedalthagaﬁ4,5,6, Jeremiah Wala 2,3, Will J. Gibson2,3, Pankaj K. Agarwalla2,7,
Peleg Horowitz 8, Steven E. Schumacher2,3, Ekaterina Esaulova9,10, Yu Mei1, Aaron Chevalier3, Matthew A. Ducar11, Aaron R. Thorner11,
Paul van Hummelen11, Anat O. Stemmer-Rachamimov12, Maksym Artyomov9, Ossama Al-Mefty1, Gavin P. Dunn9,13,14,
Sandro Santagata4, Ian F. Dunn1 and Rameen Beroukhim2,3,15
High-grade meningiomas frequently recur and are associated with high rates of morbidity and mortality. To determine the factors
that promote the development and evolution of these tumors, we analyzed the genomes of 134 high-grade meningiomas and
compared this information with data from 595 previously published meningiomas. High-grade meningiomas had a higher mutation
burden than low-grade meningiomas but did not harbor any signiﬁcantly mutated genes aside from NF2. High-grade meningiomas
also possessed signiﬁcantly elevated rates of chromosomal gains and losses, especially among tumors with monosomy 22.
Meningiomas previously treated with adjuvant radiation had signiﬁcantly more copy number alterations than radiation-induced or
radiation-naïve meningiomas. Across serial recurrences, genomic disruption preceded the emergence of nearly all mutations,
remained largely uniform across time, and when present in low-grade meningiomas correlated with subsequent progression to a
higher grade. In contrast to the largely stable copy number alterations, mutations were strikingly heterogeneous across tumor
recurrences, likely due to extensive geographic heterogeneity in the primary tumor. While high-grade meningiomas harbored
signiﬁcantly fewer overtly targetable alterations than low-grade meningiomas, they contained numerous mutations that are
predicted to be neoantigens, suggesting that immunologic targeting may be of therapeutic value.
npj Genomic Medicine  (2017) 2:15 ; doi:10.1038/s41525-017-0014-7
INTRODUCTION
Meningiomas, tumors arising from the arachnoid cap cells that
surround the brain, are the most common primary tumor of the
central nervous system.1 The majority of meningiomas are low-
grade (grade I) neoplasms that may be effectively managed by
surgical resection. A signiﬁcant subset of meningiomas, however,
have aggressive features and are associated with insidious growth,
frequent recurrence, and poor progression-free survival (grade
II–III).2 Despite the greater recurrence rates and mortality that
results from high-grade meningiomas, our understanding of the
genomic aberrations that drive these tumors remains incomplete.
Numerous clinical trials have failed to identify systemic medical
therapies that can effectively control the relentless growth of
these tumors.3
The discovery that mutation of the NF2 gene was responsible
for Neuroﬁbromatosis 2, an inherited genetic disorder character-
ized by the development of schwannomas and meningiomas, was
a substantial step forward in the characterization of the
pathobiology of meningioma and marked these tumors as one
of the ﬁrst to be associated with a genomic driver.4 Subsequent
analyses of sporadic meningiomas identiﬁed inactivating muta-
tions and copy loss of the region on 22q harboring the NF2 gene
in approximately 40–60% of cases.5–7 Recently, our group and
others used next-generation sequencing methods to identify
recurrent mutations in several additional genes besides NF2,
including v-Akt murine thymoma viral oncogene homolog 1 (AKT1)
and 3 (AKT3), Phosphatidylinositol 3-kinase (PIK3CA), Smoothened
(SMO), SUFU negative regulator of hedgehog signaling (SUFU), TNF
receptor-associated factor 7 (TRAF7), Kruppel-like factor 4 (KLF4),
SWI/SNF-related, matrix-associated, actin-dependent regulator of
chromatin, subfamily b, member 1 (SMARCB1), RNA polymerase II
subunit A (POLR2A) and BRCA1-associated protein 1 (BAP1), in
addition to alterations in the promoter region of the Telomerase
reverse transcriptase (TERT) gene.6–11 Notably, mutations in AKT1,
PIK3CA, and SMO are associated with downstream activation of
proto-oncogenic pathways, making these proteins logical targets
for attempts at pharmacologic inhibition.
However, these alterations have been observed predominantly
in low-grade meningiomas, while the genomic landscape of high-
grade meningiomas remains largely unexplored. Little is known
about the differences in driver alterations between low-grade and
high-grade tumors, whether there are speciﬁc genetic events that
are correlated with progression to higher grade, or how these
tumors respond to treatment, speciﬁcally surgical resection
followed by radiation. To address these questions, we genomically
characterized a large cohort of sporadic high-grade meningiomas
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in order to identify mutations, copy number alterations, and
rearrangements, as well to chart their evolution over time, with
the goal of furthering our understanding of the most aggressive
forms of meningioma.
RESULTS
We performed genome-level sequencing using either whole
genome sequencing (WGS) or whole exome sequencing (WES)
on 66 samples from 39 individuals with high-grade meningiomas.
Tumors from nine of these individuals were analyzed with WGS
(mean coverage of 37×). Three of these individuals also had
tumors that were analyzed with WES and an additional 30 patients
had tumors analyzed with WES. In all, a total of 57 meningiomas
were characterized with WES (mean coverage of 91×). Eleven of
the patients had multiple recurrences that were sequenced. We also
sequenced selected genes in 76 additional high-grade meningio-
mas for a total of 134 high-grade meningiomas (Supplementary
Table 1 and Supplementary Fig. 1). We compared the data derived
from these 134 samples to previously published data from
595 sporadic meningiomas proﬁled with whole genome or WES
(108 low-grade and 22 high-grade tumors), and targeted capture
sequencing (348 low-grade and 117 high-grade tumors).6, 7, 9–12 We
used these data to characterize somatic mutations (including
insertions and deletions), somatic copy number alterations
(SCNAs), and rearrangements genome-wide.
High-grade meningiomas exhibit a relatively high somatic
mutation burden with few recurrent events
Across 39 high-grade meningiomas from unique individuals, we
observed an average of 23 (range 1–223) nonsynonymous coding
alterations. This is a signiﬁcantly higher rate than in low-grade
meningiomas and comparable to that of thyroid cancer and
craniopharyngioma, but lower than that seen in head and neck
tumors, colorectal carcinoma, and melanoma (Fig. 1a).6, 13 The
mutations tended to be C>T transitions (Supplementary Fig. 2A), a
change shown to result from the increased rate of deamination of
cytosine relative to other bases, and which represents the most
common mutational signature found in an analysis of over 30
different cancer types.14
We observed one sample with a mutation load that was
signiﬁcantly greater than the rest of the cohort. This hypermutator
phenotype did not correspond to a change in the overall
mutational signature of this tumor compared with the rest of
the cohort (Supplementary Fig. 2B). We also did not identify any
mismatch repair pathway alterations in this sample, which have
been shown to produce elevated rates of mutations in other
cancer types.15
Meningiomas exposed to adjuvant radiation exhibited a higher
mutation burden (mean of 23) than both radiation-naïve
meningiomas and tumors that arose in patients who had received
prior radiation treatment to the brain, commonly referred to as
“radiation-induced meningiomas” (mean of 14, p = 0.001; Fig. 1b).
We did not detect signiﬁcant differences in mutational signatures
between irradiated and non-irradiated samples (Supplementary
Fig. 2C).
The most frequently mutated gene among these 39 tumors was
NF2, which was mutated in 46% of samples. Of the 18 NF2
alterations, 89% were inactivating frame-shift, splice site, or
nonsense alterations, consistent with the known tumor suppressor
role of NF2, compared with only 16% of non-NF2 mutations (p =
6 × 10−10). The average allelic fraction of NF2 alterations was 57%
(range 19–84%), in comparison with the cohort-wide average of
25% among all other mutations (p = 3.7 × 10−6), suggesting that
NF2 mutations tend to be shared by a larger fraction of cells in the
tumor relative to other mutations. There was no signiﬁcant
difference in mutation burden between samples with and without
NF2 mutations or chromosome 22 loss (p = 0.34, Fig. 1c).
In addition to NF2, 54 genes exhibited recurrent mutations
(range 2–4, Supplementary Table 2). However, none of these
genes reached a signiﬁcant level of recurrence after accounting
for gene-speciﬁc mutation rates and multiple hypothesis correc-
tion (see “Methods”).
Next, we performed targeted sequencing (mean coverage of
185x) of 34 of the recurrently mutated genes that we had
identiﬁed in the discovery cohort in an additional cohort of 76
independent high-grade meningioma samples (72 grade II, 4
grade III; Supplementary Tables 1 and 3). Aside from NF2, none of
these 34 genes harbored signiﬁcantly recurrent mutations in the
combined discovery and extension cohorts. NF2 was mutated in
53% (62/115) of all samples at an average allelic fraction of 55%,
compared with allelic fractions of 26% among all other genes (p <
1 × 10−16). Other than NF2, the most frequently mutated genes
were CDC27 and LRP1B, mutated in 10 (9%) and 9 (8%) samples,
respectively, of the total set of 115 meningiomas (Supplementary
Table 4). Both of these genes undergo high rates of mutation
across cancer types, likely due to a high background rate of
mutation.16
High-grade and low-grade meningiomas differ in genomic proﬁle
The ﬁnding that no genes other than NF2 were signiﬁcantly
mutated in high-grade meningiomas suggests that high-grade
meningiomas are much less likely to harbor mutations in known
drivers of low-grade meningioma, including TRAF7, KLF4, AKT1, or
SMO. To evaluate this possibility, we sequenced these genes,
which are the four most common non-NF2 driver alterations, in
our extension cohort of 76 samples. We then integrated the data
with previously published sequencing data from 595 additional
meningiomas.6, 7, 9, 10, 12 For each gene, we compared rates of
mutation among both high-grade and low-grade meningiomas
(Fig. 1d).6, 7 Mutations in each of these genes occurred
signiﬁcantly less frequently in high-grade meningiomas (p = 0.03
for each, Fig. 1e). Among these genes, TRAF7 was mutated most
frequently among the high-grade meningiomas, but only in 10 of
the 254 samples (4%).
Conversely, alterations in NF2 or chromosome 22 occurred
signiﬁcantly more frequently in high-grade (80%) than low-grade
meningiomas (43%, p < 1 × 10−16; Fig. 1f). Such elevated rates of
NF2 driver events may partly explain why non-NF2 driver genes
are mutated signiﬁcantly less frequently in high-grade than low-
grade tumors: the non-NF2 drivers are mutated most often in NF2
wild-type tumors (Fig. 1d), and there are fewer such tumors
among high-grade cases (Supplementary Fig. 3A).6, 7 However,
even among high-grade tumors without NF2 alterations, the
difference in rates of non-NF2 driver mutations remained
statistically signiﬁcant (p < 3 × 10−5).
Across the cohort of 702 high-grade and low-grade meningio-
mas from unique patients, loss of chromosome 22 and mutations
in NF2 tended to co-occur (p < 2 × 10−16). The presence of a
mutation in any of the four non-NF2 drivers was anti-correlated
with the presence of an NF2 mutation (p < 2 × 10−16) and with
loss of chromosome 22 (p < 2 × 10−16). Even in the 309 meningio-
mas with chromosome 22 loss, these canonical non-NF2
mutations were mutually exclusive with NF2 mutations (p = 0.02),
suggesting that loss of chromosome 22 may not be driving bi-
allelic inactivation of NF2 in tumors with non-NF2 driver
alterations.
We further evaluated an additional 143 genes that have been
reported to be altered in low-grade or high-grade meningioma, or
were in the same pathways as known meningioma drivers, in 201
meningiomas (Supplementary Table 3). We detected 25 altera-
tions in the mTOR pathway (including mutations in AKT1, PIK3CA,
MTOR, TSC2, and RICTOR), 16 alterations in the Hedgehog pathway
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(including mutations in SMO and SUFU), and two mutations in
TP53, which is downstream of KLF4. However, mutations in these
pathways were not signiﬁcantly enriched above the background
rate (Fig. 1g).
The lack of signiﬁcantly recurrent mutations, other than in NF2,
among high-grade tumors indicates that it is unlikely that any
individual gene is mutated in more than 20% of high-grade
tumors. We did not ﬁnd any genes other than NF2 mutated in
Meningioma genomics
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more than 10 patients, which would represent a mutation rate of
13%. We had 95% power to detect genes mutated in at least 19%
of patients, and 50% power to detect genes mutated in 13% of
patients (Supplementary Fig. 3B).
High-grade meningiomas demonstrate frequent copy number
alterations
We next investigated chromosomal instability across meningio-
mas (Fig. 2a). Similar to mutation burden, high-grade meningio-
mas have signiﬁcantly higher levels of genomic disruption than
low-grade meningiomas (3% vs. 19%, p < 1 × 10−8), and disruption
rates comparable to other aggressive systemic and CNS cancers
such as glioblastoma (Fig. 2b).17
Loss of chromosome 22 was the most frequent arm-level SCNA,
observed in 56% of 702 sequenced meningiomas (Fig. 1d). Losses
of chromosomes 1p, 6q, 10q, and 18q, along with gains of 17q and
20q, were also recurrent across high-grade meningiomas (Fig. 2c),
consistent with previous cytogenetic studies.18 High-grade
meningiomas harbored loss of chromosome 22 more frequently
(87%) than low-grade meningiomas (58%, p = 0.03), with chromo-
some 1p loss being the second most common SCNA. We did not
detect any signiﬁcantly recurrent focal copy number alterations.
Within our high-grade meningioma cohort, 7 tumors were
considered radiation-induced, as they originated following distant
exposure to therapeutic radiation for other reasons, and 11 tumors
were treated with radiation following an initial diagnosis of
meningioma. Meningiomas treated with adjuvant radiation
exhibited a signiﬁcantly higher burden of copy number alterations
than radiation-induced or non-irradiated meningiomas (p = 0.02,
Fig. 2d). While there was no signiﬁcant difference in genomic
disruption between NF2-mutant and NF2-wild-type samples,
meningiomas with chromosome 22 loss demonstrated increased
rates of genomic disruption, even after excluding chromosome 22
(p = 0.05, Fig. 2e).
Complex rearrangements are prevalent in both low-grade and
high-grade meningiomas
We next sought to determine the burden of rearrangements in 19
meningiomas (8 high-grade, 11 low-grade) with WGS data (Fig. 3a).
We detected a median of 21.5 rearrangements per high-grade
tumor (range 0–217, SD = 72), compared with ﬁve rearrangements
per low-grade tumor (range 0–39, SD = 12; p = 0.15), for a total of
446 distinct rearrangements across our cohort (Supplementary
Table 5A). Translocations (interchromosomal rearrangements)
represented 35% (157 of 446) of these events. Among the
intrachromosomal rearrangements, deletions were the most
common (26%), followed by inversions and duplications (20 and
11%, respectively; Supplementary Fig. 4A–B).
NF2 was the most frequently rearranged gene across our cohort
(n = 4). These rearrangements all occurred in samples with
chromosome 22 loss and never in conjunction with mutations
or indels in NF2, indicating that they likely represented a second
hit resulting in bi-allelic NF2 inactivation.
We also detected recurrent rearrangements in 11 additional
genes. These included three patients with rearrangements in the
microtubule-associated GTPase DNM3, which is likely a fragile site.
The remaining 10 genes were each rearranged in two patients,
including the serine/threonine kinase CDK14, the neuronal growth
regulator NEGR1, and the Rho GTPase family guanine nucleotide
exchange factor VAV3 (Supplementary Table 5B).
Prior work has demonstrated that rearrangements can some-
times occur as part of a single, catastrophic event. These
phenomena include chromothripsis, where focal regions of one
or two chromosomes are highly rearranged, and chromoplexy,
which affects multiple chromosomes.19, 20 We classiﬁed groups of
rearrangements with at least four linked alterations as part of a
complex event (Fig. 3b). More than half (227 of 399; 57%) of all
detected rearrangements were the result of a relatively small
number of unique complex events (Fig. 3c). We detected 8 such
events across our cohort, with a mean of 43 (median 24) individual
rearrangements in each. The median number of rearrangements
in meningiomas with complex events was signiﬁcantly greater
than in tumors without complex events (24 vs. 8, p = 0.03), and
complex events were responsible for an average of 55% (range
22–100%) of the rearrangements in the samples in which they
occurred.
One sample had 212 rearrangements and contributed more
than half of the total observed rearrangements across all samples.
It also had a highly disrupted copy number proﬁle (Supplementary
Fig. 4D). This sample harbored a TP53G187S mutation, which has
been shown to be a recurrent TP53 alteration across cancers.21
Alterations in p53 have not been found to be signiﬁcantly
recurrent in meningioma, but this alteration may explain the
signiﬁcant rates of disruption found in this sample. Nearly 75% of
all rearrangements in this sample were due to a complex cluster
that spanned seven different chromosomes (Fig. 3d).
Indeed, across the cohort, complex events often linked together
geographically distinct regions of the genome, and on average
included events from four chromosomes. We found that 53% of
complex events were translocations, compared with only 21% of
isolated events (p = 5 × 10−11; Supplementary Fig. 4C), largely as a
result of the hyper-rearranged sample, in which 65% of complex
rearrangements were translocations.
We next sought to categorize the mechanistic basis of detected
rearrangements. Brieﬂy, we classiﬁed the genomic context of each
rearrangement according to the degree of sequence homology,
overlap with repetitive elements, and size of junction insertion in
order to characterize the biological double-strand break repair
mechanism most likely to have generated it, according to
previously described methods.22 Previous work analyzing 10
cancer types has suggested that micro-homology-mediated end
joining (MMEJ) and non-homologous end joining (NHEJ) are the
most frequent drivers of somatic rearrangements (41 and 39%,
respectively). Using our own rearrangement detection pipeline,
we likewise found that the majority (>90%) of observed
rearrangements in meningioma have signatures consistent with
MMEJ and NHEJ repair processes (Fig. 3e). Low-grade and high-
grade meningiomas did not signiﬁcantly differ in the composition
(inversion, deletion, duplication, or translocation) or inferred
mechanistic basis (MMEJ, NHEJ) of the detected rearrangements.
Fig. 1 Mutational characteristics of high-grade meningioma. a Nonsynonymous mutation counts (y-axis) per sample for a selection of tumor
types (x-axis). b Nonsynonymous mutation counts (y-axis) for meningiomas stratiﬁed by prior radiation exposure (x-axis). c Nonsynonymous
mutation counts (y-axis) for meningiomas with or without NF2 mutations or chromosome 22 loss (x-axis). d Chromosome 22 loss or canonical
meningioma gene mutation (y-axis) across 702 aggregated samples (x-axis); each column represents one sample and white space indicates lack
of coverage. e Percentage of samples (y-axis) with NF2 mutation or chromosome 22 loss stratiﬁed by grade (x-axis). f Percentage of samples (y-
axis) with non-NF2 driver mutations stratiﬁed by grade (x-axis). g Presence of mutations in meningioma-associated pathways (y-axis) across
200 samples with genomic characterization (x-axis). Dark colors correspond to canonical alterations; lighter hues represent non-canonical
alterations in the pathway. Lg meningioma low-grade meningioma, Hg meningioma high-grade meningioma, wt wild-type, mut mutant, n.s. not
signiﬁcant. Error bars and central values represent mean with s.e.m. (a) or median with i.q.r. (b, c)
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Meningiomas exhibit substantial heterogeneity across space and
time.
We next focused on 11 patients in our cohort with two or
more serial meningioma resections (Supplementary Table 6).
On average, 23% of speciﬁc mutations (range 5–77%) were
shared across any pair of samples from the same patient
(Fig. 4a). This heterogeneity is not an artifact of tumor impurity
(see Supplementary Note 1), and represents a much higher
Meningioma genomics
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level of heterogeneity than seen in many other cancer types
(Fig. 4b).23–29
This heterogeneity could represent the appearance of new
mutations over time, or it could represent geographic hetero-
geneity in the initial tumor. If the appearance of mutations over
time were driving the observed heterogeneity, we would expect
later tumors to exhibit a greater mutation burden than earlier
tumors. However, we did not observe a statistically signiﬁcant
increase in the number of mutations between subsequent
samples (Supplementary Fig. 5).
These results suggest that the observed heterogeneity is primarily
spatial. To evaluate the contribution of spatial heterogeneity, we
assessed four distinct areas from the same resection of a single
patient and found that only 9% of the mutations were shared
between any two of the regions. To validate this ﬁnding, we
aggregated all samples in our cohort that had previously been
characterized by next-generation sequencing of a custom cancer
gene panel. This prior sequencing was done with DNA obtained
from a different region of the same formalin-ﬁxed parafﬁn
embedded (FFPE) core, thus lending insight into the spatial
heterogeneity of these tumors. We observed a striking dichotomy
in rates of overlap between driver and passenger mutations. In
particular, we found that 21 of 22 (95%) driver mutations were
shared across cores from the same sample, compared with only 18/
61 (30%) of putative passenger alterations that were covered by the
targeted sequencing panel (p = 0.0001, Supplementary Table 7).
The ﬁnding that NF2 is the most frequently altered gene in low-
grade and high-grade meningiomas, combined with the ﬁnding
that these mutations tend to have high allelic fractions and nearly
always co-occur with loss of the wild-type copy of chromosome
22, has led to the presumption that NF2 mutations are an initiating
event in meningioma tumorigenesis. However, we observed three
distinct inactivating NF2 alterations across ﬁve recurrences in one
patient (MEN0045). Conversely, all copy number alterations were
shared by all recurrences in this patient. For this patient, the data
suggest that NF2 mutation, and thus bi-allelic inactivation, was not
the initiating event, but was instead preceded by widespread
genomic disruption.
Recurrent tumors demonstrated little variation in copy number
proﬁles, with any two samples from the same patient sharing an
average 75% of arm-level SCNAs. This represents a signiﬁcantly
elevated rate of overlap compared with mutations (Fig. 4a vs. 4c),
where only 23% were shared across paired samples on average (p
< 2 × 10−5; Fig. 4d), and suggests that SCNAs precede most non-
driver mutations during the development of high-grade
meningiomas.30
The homogeneity in copy number proﬁle was observed even in
samples that recurred at higher grade. Most low-grade menin-
gioma tended to have few arm-level events other than loss of
chromosome 22. However, those low-grade samples that later
recurred as higher-grade meningiomas had signiﬁcantly elevated
rates of copy number alterations compared with tumors which did
not (p < 0.0001; Fig. 4e).
Temporal relationships indicate survival of multiple lineages
across resections
Successive recurrences of the same meningioma may comprise
either a single invasive subclone that develops a growth
advantage compared with other initially co-existing subclones,
or different subclones that are present in geographically distinct
regions of the primary meningioma which can each subsequently
emerge. In the former case, one would expect successive
resections to be more closely related to each other than to the
primary resection, whereas the latter case would imply a random
ordering to the relationships between successive resections
(Fig. 5a).
To distinguish between these possibilities, we constructed
phylogenetic trees to assess the evolution of tumors over time
among six patients for whom we had sequenced more than two
recurrences. In ﬁve of the six cases, we found that samples that did
not immediately precede one another were the most closely
related (Supplementary Fig. 6). For example, in one case, the ﬁfth
and third resection were more similar to one another than to any
of the other sequenced samples (Fig. 5b). In another, the primary
tumor and fourth resection were more similar to one another than
to the third resection (Fig. 5c). These results suggest that
subsequent recurrences reﬂect geographically distinct unresected
regions rather than a dominant invasive subclone that originates
from the primary tumor.
Genomic features associate with high-grade meningioma subtype
and location
It is increasingly appreciated that the driver mutations of
meningiomas are associated with particular histopathologic
subtypes and with anatomic locations in the cranium.6, 7, 9, 18
Recent work has shown that a subset of rhabdoid meningiomas,
but not meningiomas of other histological subtypes, harbor
mutations in the tumor suppressor gene BAP1.11 Across high-
grade meningiomas, we found that the rhabdoid subtype was
associated with a signiﬁcantly lower incidence of chromosome 1p
losses compared with other high-grade meningiomas (p = 0.002,
Fig. 2a), consistent with a distinct pathogenesis. Angiomatous
meningiomas also demonstrated a markedly different copy
number proﬁle from other meningiomas, with frequent arm-
level gains, consistent with previous cytogenetics observations.31
These spanned both classic grade I angiomatous meningiomas as
well as meningiomas with angiomatous features that fulﬁlled
histologic criteria for grade II.
High-grade meningiomas in our cohort were also signiﬁcantly
more likely to exhibit a paravenous origin (including parasagittal,
falcine, torcula, and intraventricular locations), and signiﬁcantly
less likely to originate in the anterior skull base (including olfactory
groove, clinoid, planum, tuberculum), than low-grade meningioma
(p < 3 × 107).
Across the 702 aggregated samples, low-grade meningiomas
were signiﬁcantly more likely to occur in females compared with
males, in line with previous reports. We also validated the
association between AKT1/PIK3CA mutations and meningothelial
subtype (p < 0.001), NF2 mutations with ﬁbroblastic subtype (p <
0.001), and mutations in TRAF7/KLF4 and secretory subtype (p <
0.001). We did not detect additional associations between age or
gender and chromosomal disruption, mutation burden, location,
or speciﬁc driver alterations.
Furthermore, we did not detect a signiﬁcant difference in
recurrence rates between high-grade meningiomas with canonical
low-grade driver alterations and those without, or between NF2-
Fig. 2 Landscape of copy number alterations in meningioma. a Heatmap of gains (red) and losses (blue) across the genome (y-axis) for
56 samples (x-axis) with whole exome or WGS. Pathological features, primary or recurrent status, and exposure to distant (radiation-induced)
or recent adjuvant radiation are annotated. b Percent genome disrupted (y-axis) for low-grade and high-grade meningiomas, as compared
with eight other cancers (x-axis). c Percent incidence (x-axis) of chromosome arm-level gains and losses (y-axis). d Percent of genome
disrupted (y-axis) for meningiomas stratiﬁed by radiation exposure (x-axis). e Percent of genome disrupted (y-axis) for meningiomas stratiﬁed
by NF2 mutation or chromosome 22 loss (x-axis); angiomatous meningiomas were excluded due to their markedly different genomic proﬁle.
AML acute myeloid leukemia, Lg meningioma low-grade meningioma, Hg meningioma high-grade meningioma, GBM glioblastoma, n.s. not
signiﬁcant. Error bars and central values represent mean with s.e.m
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mutant and NF2-wild-type low-grade meningiomas. However, we
had limited power to assess such relationships as a result of the
relatively low recurrence rate observed in our cohort, in part due
to our limited follow-up time.
Genomic basis for therapeutic options in high-grade meningiomas
We next assessed the percentage of high-grade tumors with
potentially targetable alterations. We ﬁrst considered the
signiﬁcantly recurrent genetic alterations that are targets of
Meningioma genomics
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existing clinical therapeutics (AKT1, SMO, or PIK3CA). Relative to
low-grade meningiomas, fewer high-grade meningiomas had
mutations in these genes (17 vs. 5%; p < 8 × 10−5). We did observe
isolated mutations in other members of these pathways in our
high-grade extension cohort (Fig. 2e). However, their rates of
mutation were also low (8.5% at most) and did not reach statistical
signiﬁcance.
We then characterized the putative neoantigen burden of high-
grade meningiomas using a cancer immunogenomics approach,
which has been shown to predict response to immunotherapy in
melanoma,32 colorectal cancer,33 lung cancer,34 and in small
subsets of brain tumor patients.35, 36 We used WES data to impute
the human leukocyte antigen (HLA) type of each patient to predict
which mutations could represent candidate neoantigens (Supple-
mentary Table 8; see “Methods”). Across our high-grade cohort,
66% of mutations were predicted to be neoantigenic, and each
sample had on average 87 such mutations (range 2–587). This
represents a signiﬁcant increase in putative neoantigen load
compared with low-grade meningioma (mean = 8.4, p = 0.03;
Fig. 6a) and was due primarily to the increased mutation burden
of high-grade tumors, rather than to speciﬁc mutational processes
that produced an increased rate of potentially immunogenic
alterations. The fraction of mutations that could serve as
neoantigens did not differ between low-grade and high-grade
meningiomas (Fig. 6b).
To determine the relevance of these proposed neoantigens, we
examined previously published expression data from a cohort of
meningiomas.37 We calculated the overlap between genes with
putative neoantigens in our cohort with those that were
expressed in this prior cohort. We found that 76% of the genes
with proposed neoantigens were expressed.
We next sought to determine whether these predicted neo-
epitopes could represent robust substrates for immune targeting.
Recent work has demonstrated that the presence of clonal
neoantigens is correlated with overall survival.38 Interestingly,
mutations predicted to be neoantigenic were more likely to be
clonal than other mutations (20 vs. 11%, p < 0.001; Fig. 6c). Indeed,
each sample had an average of 10 clonal mutations (range 1–71),
suggesting that faithful markers that distinguish tumor cells from
normal cells may exist for the majority of meningioma.
To further elucidate the potential for immune targeting of these
neoantigens, we examined our cohort of serial recurrences in
which we had shown that the speciﬁc mutations vary signiﬁcantly
from recurrence to recurrence in meningioma. Consistent with the
lack of signiﬁcantly recurrent mutations across patients, we found
that relatively few of these putative neoantigens (2%) were
identiﬁed in samples from more than one patient. However, the
overall predicted neoantigen burden was relatively constant
across samples from the same patient (Fig. 6d), demonstrating
that even with variation of speciﬁc immunogenic alterations, the
relative incidence of targetable alterations remains stable from
sample to sample.
DISCUSSION
We performed next-generation sequencing on nearly 140 high-
grade meningiomas, and found that they harbored elevated rates
of mutations and copy number alterations compared with low-
grade samples. Furthermore, the relative importance of speciﬁc
driver alterations identiﬁed were markedly different across grades.
Our data and previous publications support a model of
meningioma formation in which PI3-kinase and Hedgehog path-
way alterations are mostly restricted to low-grade tumors, NF2
mutations and genomic disruption are enriched among high-
grade tumors, and mutations of chromatin modiﬁers are observed
across grades.6, 7, 9, 10
The major consistent genetic distinction between high-grade
(grade II–III) and low-grade (grade I) meningiomas is the presence
of widespread genomic disruption in aggressive meningiomas.
Moreover, low-grade meningiomas which progressed to a higher
grade on recurrence harbored disrupted copy number proﬁles that
closely resembled their high-grade counterparts. Molecular classi-
ﬁcation of tumors has shown great promise for risk stratiﬁcation
across a variety of cancer types. We have previously shown that the
degree of genomic disruption predicts subsequent recurrence in
atypical meningioma.39 In our present study, we extend this
analysis to low-grade tumors. The ability to differentiate the
recurrence risk of meningioma by their copy number proﬁles may
help augment traditional histopathological recurrence risk assess-
ment, with consequent impact on management decisions.
When present, NF2 alterations are believed to be the initiating
event in meningiomagenesis, in part because germline alterations
in NF2 cause Neuroﬁbromatosis 2, characterized by frequent
meningiomas and schwannomas. However, genomic disruption
tends to occur earlier in tumor evolution than do most mutations,
and in one case, we observed three distinct NF2 alterations across
multiple recurrences in the setting of an identical copy number
proﬁle (Supplementary Fig. 6C). These ﬁndings suggest a model
wherein high-grade meningiomas are initiated by widespread
genomic disruption, followed by expansion of cells that then
acquire NF2 and other mutations. Further investigation will be
necessary to determine whether widespread copy number
alterations, or NF2 mutations, tend to be earlier events in sporadic
high-grade meningiomas.
Of the widespread genomic disruption observed in high-grade
meningioma, the single most frequent event is arm-level loss of
chromosome 22, which is postulated to drive bi-allelic inactivation
of NF2. In line with this hypothesis, we found that mutations in
NF2 occur in 75% of meningiomas with loss of chromosome 22,
but in less than 1% of samples without such loss. It is possible that
the 25% of meningiomas with chromosome 22 loss that do not
exhibit NF2 mutations nevertheless contain cryptic NF2-inactivat-
ing events. Indeed, among meningiomas that had undergone
WGS, every meningioma with loss of chromosome 22 exhibited
inactivation of NF2. In four cases (27%), this inactivation was due
to truncating rearrangements that may not be detectable by
targeted sequencing.
However, it is also possible that chromosome 22 loss targets
additional tumor suppressors. In principle, if inactivation of the
second copy of NF2 was the sole driver of chromosome 22 loss,
then this could be accomplished by either arm-level losses, or
through focal loss of the area surrounding NF2—but we observed
no focal losses of NF2 in any of the 56 tumors for which we had
copy number proﬁling data. The possibility that chromosome 22
loss provides selective beneﬁt in addition to loss of NF2 is also
supported by patterns of non-NF2 driver mutations. Among
tumors with chromosome 22 loss, we detected non-NF2 driver
mutations at a higher rate in meningiomas without NF2 mutations
Fig. 3 Characteristics of meningioma rearrangements. a Representative Circos plots for three samples (MEN0042, MEN0011, MEN0053), with
lines between genomic coordinates representing intrachromosomal (orange) or interchromosomal (blue) rearrangements. b Example of a
complex event involving multiple genomic positions (x-axis) with associated changes in read coverage (y-axis). c Number of rearrangements
(y-axis) per sample (x-axis) broken down by complex (orange) or simple (blue) event type. d Circos plot of a hyper-rearranged grade III
meningioma and the deconstruction of complex and simple rearrangements to the overall makeup of this sample. e Percent incidence of
different mechanisms driving rearrangement formation (y-axis) across multiple cancer types (x-axis). MMEJ micro-homology-mediated end
joining, NHEJ non-homologous end joining, MMBIR micro-homology-mediated break-induced repair
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than in meningiomas with NF2 mutations, suggesting that NF2
was not equivalently inactivated in the two groups. Several
meningioma tumor suppressors on chromosome 22 have been
proposed, including SMARCB1, CHEK2, and CLH22.40, 41 CHEK2 halts
cell-cycle progression in the presence of DNA damage, so loss of
CHEK2 would likely be associated with increased genomic
disruption. Indeed, we observed increased genomic disruption
among meningiomas with loss of chromosome 22.
The relative paucity of mutations in the non-NF2 driver genes
among high-grade tumors has implications for clinical care. mTOR
pathway inhibitors are under clinical trial in recurrent and
progressive meningiomas with AKT1 or PI3K pathway alterations.
The low incidence of such alterations in high-grade tumors means
that enrollment in such trials on the basis of these mutations will
require large multicenter trials. We identiﬁed mutations in
additional, previously unreported pathway members of these
genes, but they did not reach statistical signiﬁcance. Larger
cohorts which are powered for detection of low-frequency events
will be necessary to determine whether these mutations are also
drivers of meningiomagenesis and therefore may represent
alternative avenues of therapeutic potential.
Both angiomatous and rhabdoid meningiomas present distinct
copy number proﬁles compared with other histologic subtypes.
Angiomatous meningiomas are typically considered to be grade I,
although emerging data suggest the existence of grade II
meningiomas with angiomatous features based on the presence
of copy number changes such as monosomy 14 that are
traditionally found in higher grade meningiomas. Independent
of histologic grade, we observe frequent gains across the genome
in multiple chromosomes in angiomatous meningiomas.
Fig. 4 Intra-patient heterogeneity in meningioma. a Mutation count (y-axis) across 11 recurrent samples (x-axis) for mutations that are present
in all biopsies (ubiquitous, red), some biopsies (shared, teal), or only a single biopsy (private, blue). b Percent of mutations shared from pairs of
samples from the same patient (y-axis) across a variety of diverse cancer types (x-axis).15–17, 19, 20, 22, 23 c SCNA count (y-axis) across 11 recurrent
samples (x-axis) for SCNAs that are present in all biopsies (ubiquitous, red), some biopsies (shared, teal), or only a single biopsy (private, blue). d
Cumulative percentage of events per patient (y-axis) as a function of the percentage of samples examined (x-axis) for mutations (red) and
SCNAs (teal). e Percent of genome disrupted (y-axis) for low-grade meningiomas, stratiﬁed by whether or not they went on to recur (x-axis).
Error bars and central values represent mean with s.e.m
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Rhabdoid meningiomas are considered to be grade III tumors by
WHO guidelines,42 but recent reports have proposed that the
histolopathologic ﬁnding of rhabdoid features may be found in
meningiomas of each of the three WHO grades. In our cohort,
rhabdoid meningiomas harbored loss of chromosome 1p sig-
niﬁcantly less frequently than grade II–III meningiomas of other
histologic subtypes. These observations support a role for the
incorporation of genetic criteria in meningioma classiﬁcation.
Recent work has also demonstrated that the molecular
classiﬁcation of meningioma extends beyond the genome.43 An
integrated genomic analysis of grade II atypical meningiomas
found that these tumors harbored distinct patterns of both DNA
methylation and RNA expression compared with grade I tumors.
This may contribute to the variable clinical outcomes that result
from tumors with similar genomic proﬁles. Interestingly, copy
number alterations appear to drive some, but not all, of these
changes, implying that the mechanistic trigger for these
differential cell states remains to be elucidated.
The appropriate classiﬁcation, biological course, and adjuvant
treatment options for radiation-induced meningiomas remains a
challenge for clinicians. We found that the copy number burden of
radiation-induced meningiomas is similar to radiation-naïve
meningiomas, and is signiﬁcantly lower than tumors previously
exposed to therapeutic adjuvant radiation. This suggests that the
Fig. 5 Phylogenetic analysis of recurrent meningioma. a Schematic illustrating the expected phylogenetic relationship across successive
recurrences if a tumor evolves through progressive dominance of an invasive subclone (top) compared with outgrowth of subclones from a
geographically heterogeneous primary (bottom). b Patient with a multiply recurrent parasagittal anaplastic meningioma that underwent serial
resections as well as interval radiation (XRT) and sunitinib (chemo). Pre-operative and post-operative MR imaging (top) from the third (S3),
fourth (S4), ﬁfth (S5), and sixth (S6) resections, spanning a 4-year interval, demonstrates a heterogeneous pattern and location of tumor
regrowth despite excellent resections. Phylogenetic tree (bottom) demonstrates a branched evolution of the mutations associated with each
tumor resection (S3–S6). c Pre-operative and post-operative MRIs (top) and phylogenetic tree (bottom) of four serial resections (S1–S4) over 6
years in a patient with recurrent rhabdoid meningioma
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effects of radiation on the molecular makeup of meningioma may
be context-dependent and dose-dependent. Longitudinal follow-
up will be necessary to determine if the levels of genomic
disruption correspond to recurrence risk in radiation-induced
meningiomas.
We observed no clear statistical evidence for clonal outgrowth
between recurrences. In other cancer types, resistance to targeted
inhibitors often result from pre-existing clones harboring resis-
tance mutations in a background of additional mutations, and
these clones rise to prominence in the population following
treatment. The random phylogenetic ordering of multiple
recurrences implies that the surgery and radiation applied to
these tumors do not exert similarly strong bottlenecks on the
tumor population. In time, as targeted and other systemic
therapies become available for high-grade meningiomas, this
pattern of clonal outgrowth may be altered.
Finally, we present the ﬁrst analysis of predicted neoantigen
load in meningioma. We identiﬁed a number of mutations in each
meningioma that were predicted to be immunogenic. Although
true credentialing of these neoantigens will require paired
expression data and further follow-up, our work provides a
proof-of-concept that a cancer immunogenomics approach to
these tumors may be promising. Previous work has demonstrated
that high-grade meningiomas express PD-L1 and harbor exuber-
ant immune inﬁltrates.44 Clinical trials are currently enrolling for
patients with recurrent high-grade meningioma to test the
applicability of immunotherapy. Our ﬁnding that a signiﬁcant
fraction of mutations observed in high-grade meningioma is likely
to result in neo-epitope presentation provides additional evidence
for this line of therapeutic investigation. In particular, even if the
cumulative neoantigen burden does not predict a high response
to treatments such as checkpoint blockade immunotherapies,
clonal neoantigens may be robust vaccine or adoptive cellular
therapy targets. As we did not detect recurrent immunogenic
targets, these data would likely inform the design of personalized
cancer vaccines, rather than vaccines targeting shared tumor
Fig. 6 Analysis of predicted neoantigen load in meningioma. a Number of predicted neoantigens (y-axis) in low-grade and high-grade
meningioma (x-axis). b Percentage of identiﬁed neoantigens (y-axis) in low-grade and high-grade meningioma (x-axis). c Percentage of
mutations which are present in all tumor cells (y-axis) stratiﬁed by whether they are predicted to be immunogenic (x-axis). d Percentage of
mutations in the primary (x-axis) which are predicted to be neoantigens vs. percentage of mutations in matched recurrence (y-axis) which are
predicted to be neoantigens. Error bars and central values represent mean with s.e.m
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antigens. These particular efforts are currently being developed
across a number of cancer types, and therefore this approach is
conceivable for challenging meningiomas as well.45 Ongoing work
to determine the applicability of such immunotherapy approaches
will hopefully expand our therapeutic options for patients with
these challenging tumors who currently have no reliable
alternatives to surgery and radiation.
METHODS
Sample identiﬁcation
This study was reviewed and approved by the institutional review boards
of the Dana-Farber/Harvard Cancer Center, the Brigham and Women’s
Hospital, and the Broad Institute. Histopathologic diagnosis based on WHO
2007 criteria and tumor purity >80% was conﬁrmed in all samples selected
for study by two board-certiﬁed neuropathologists (S.S., M.A.). DNA was
extracted from fresh-frozen tissue shavings or FFPE cores for tumor and
paired blood buffy coat preparations or saliva for normal control DNA
using standard protocols (Qiagen, Valencia, CA) and quantiﬁed using the
PicoGreen system (Invitrogen). The tumor-normal pairs were conﬁrmed by
mass spectrometric genotypying with an established 48-SNP panel
(Sequenom, San Diego, CA).
Next-generation sequencing
A total of nine meningiomas underwent WGS, and 57 meningiomas WES,
along with DNA from matched blood or saliva, as previously described.6
DNA was sonicated to 250 bp fragments, size selected with Agencourt
AMPure XP beads, and ligated to speciﬁc barcoded adapters (Illumina
TruSeq; Illumina Inc., San Diego, CA) for multiplexed analysis. Exome hybrid
capture was performed on 76 meningiomas using the Agilent SureSelect
hybrid capture kit (Whole Exome_v4; Agilent Technologies, Santa Clara,
CA) and sequenced on a HiSeq 2500 system (Illumina Inc., San Diego, CA).
All samples achieved at least 80× coverage in exons (mean coverage =
108×).
Sequence data were aligned to the hg19 (b37) reference sequence using
the Burrows-Wheeler Aligner. Sample reads were sorted, duplicate-marked,
and indexed using SAMtools and Picard. Bias in base quality score
assignments due to ﬂowcell, lane, dinucleotide context, and machine cycle
were analyzed and recalibrated, and local realignment around insertions or
deletions (indels) was achieved using the Genome Analysis Toolkit. All
paired samples underwent quality control testing to ensure accuracy of
tumor-normal pairs.
Mutation analyses
Somatic mutations, insertions, and deletions were detected using MuTect and
IndelLocator.46 These were annotated to genes and compared with events in
the Catalogue of Somatic Mutations in Cancer (COSMIC) using Oncotator and
also veriﬁed through visualization in Integrated Genome Viewer. Mutations
with allelic fractions less than 0.1 were discarded for the purposes of driver
mutation analysis. Signiﬁcance of identiﬁed genetic alterations was assayed
using MutSig2CV, which uses patient and gene-speciﬁc mutation rates to
estimate a background model of predicted mutation incidence across the
genome.16 It then factors in biological co-variates such as replication timing
and gene-expression level on a gene-by-gene basis to account for the
increased mutational rate of certain classes of genes.
To reduce the false positive rate of mutations in our validation cohort,
samples without normal DNA were passed through a panel of normals
ﬁlter. We removed all mutations present in either the ExAC or ESP
databases.47, 48 To determine our power to detect driver mutations, we
used a binomial distribution to calculate the true mutation rate which
would produce either a 95 or 50% likelihood of success for seeing at least
15 mutations.
To calculate cohort-wide statistics, we excluded samples derived from
the same patient. In the cases in which both whole genome and WES
samples were available for the same patient, we included the whole
genome sequenced sample; otherwise, we included the earliest available
sample in our analysis (Supplementary Table 1).
Copy number analyses
To analyze SCNAs from whole exome data, we used ReCapseg,
which assesses homolog-speciﬁc copy ratios from segmental estimates
of multipoint allelic copy ratios at heterozygous loci incorporating
the statistical phasing software (BEAGLE) and population haplotype
panels (HAPMAP3).49, 50 Allele-speciﬁc SCNAs and tumor ploidy status
were assessed with ABSOLUTE.51 For copy number alteration signiﬁcance
analysis, segmented copy number data were analyzed by GISTIC 2.0,
which separately assesses the signiﬁcance of recurrent focal and
arm-level SCNAs by comparing their rates of alteration to the
overall genome-wide alteration rate. In the case of arm-level events, it
controls for the tendency for short arms to undergo more frequent
alterations.52
Calculations which compared degree of chromosomal disruption across
groups of samples did not include angiomatous meningioma, due to their
unique genomic proﬁle characterized largely by gains.
Rearrangements analyses
Rearrangement detection was performed using Snowman. Snowman
performs genome-wide unbiased local assembly with SGA and realigns
contigs to the reference using BWA-MEM.53 Aligned contigs with multi-part
or gapped alignments indicate candidate structural variants. Reads are re-
aligned to the contigs to score candidate variants and to classify events as
somatic or germline. Microhomology at the breakpoints was determined
by recording the number of bases at the junction that could be aligned to
either side of the breakpoint. Event types were determined based on
interpretation of read coverage plots paired with called rearrangements.
Classiﬁcation of the mechanistic basis of rearrangements was adapted
from Yang et al.22
Phylogenetic analyses
To determine the percentage of mutations shared by a typical pair of
samples from the same patient, we calculated the overlap of shared
mutations from all possible pairs of samples for each patient, then took the
per-patient average. CCFs were determined using ABSOLUTE, which
combines copy number data with mutations to estimate purity and ploidy
of samples. Phylogenetic trees were constructed by looking at mutations
with 95% power of detection across all samples from each patient, then
determining the phylogenetic relationship based on shared overlap. Copy
number alterations were assessed separately.
Spatial heterogeneity in the validation cohort was calculated as the
percentage of mutations identiﬁed in our current cohort that were also
identiﬁed in the earlier targeted sequencing. We excluded genes that were
not covered in the earlier gene lists. Genomic position was inferred from
protein change using TransVar (http://bioinformatics.mdanderson.org/
transvarweb).54
Mutational immunogenicity prediction
HLA alleles were called with PHLAT from exome sequencing data.55 For
each tumor, epitope predictions were made by considering interaction
between conﬁdently called HLA alleles and single-residue missense
alterations (SNV) or protein-altering indel alterations. Separate lists were
generated consisting of wild-type and mutant peptides of 8, 9, 10, and 11
amino acids in length for MHC Class I and 15 amino acids in length for
MHC Class II, as these are known to be the possible lengths for peptides
presented by human MHC.
We then predicted MHC binding afﬁnity for each of the peptides
as described previously.56 We used the NetMHC, NetMHCpan, SMM,
SMMPMBEC, and NetMHCIIpan prediction methods to predict MHC
binding afﬁnity values for each peptide and used the median value across
all algorithms as a composite measure of binding strength.57–61 We also
deﬁned the neoepitope ratio for each mutant and wild-type peptide pair
as the median afﬁnity value for the mutant peptide divided by the median
afﬁnity value for the wild-type peptide. This value was found to be a
reliable comparator of the relative immunogenicities of the mutant vs.
wild-type peptide sequences.56 Because epitope binding is HLA depen-
dent, the previous steps were performed for each of the called MHC I
proteins. After this, only peptides predicted to be the best epitopes for
each mutation were considered.
Gene expression analysis
Published data were downloaded from GEO (https://www.ncbi.nlm.nih.
gov/geo/) from accession GSE77259.37 Data were imported into Gene-
Pattern,62 then normalized using the AffySTExpressionFileCreator module,
which implements the oligo package.63 The mean for each gene was
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calculated across samples, and the bottom 25% expressing genes were
removed. We then calculated the percent overlap between genes with
putative neoantigens, and genes that were expressed.
Statistical analyses
All statistical analyses were performed using version 3.1 of the open source
R software package.64 The Student’s t-test and Wilcox log-rank tests were
used to assess differences in means. The Fisher’s exact test was used to
determine differences in count data. A binomial null distribution was used
to determine statistical power. All tests were two-sided. Non-sparse data
without signiﬁcant outliers were assumed to be normal; sparse data or
those with signiﬁcant outliers were evaluated using non-parametric tests.
Availability of data and material
All sequencing data have been deposited in the EGA repository at https://
www.ebi.ac.uk/ega/studies/EGAS00001002294. All code used for analysis
is available at https://github.com/ngreenwald/publications/Lab_Stuff/
High_Grade_Meningioma.
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